HER-096

DRUG2 trials

Sponsors

Herantis Pharma Plc.

Conditions

Parkinson DiseaseParkinson Disease, Idiopathic

Phase 1

Single Ascending Doses of HER-096 in Healthy Subjects

CompletedNCT05915247

Herantis Pharma Plc.Parkinson Disease

Start: 2023-03-29End: 2023-09-29Updated: 2023-10-27

Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease

CompletedNCT06659562

Herantis Pharma Plc.Parkinson Disease, Idiopathic

Start: 2024-09-23End: 2025-08-20Updated: 2025-09-12